Presentation is loading. Please wait.

Presentation is loading. Please wait.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Published byRalph Mosley Modified over 5 years ago

Similar presentations

Presentation on theme: "Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD "— Presentation transcript:

1 Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD  Journal of Thoracic Oncology  Volume 2, Issue 3, Pages (March 2007) DOI: /JTO.0b013e318031cd4e Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Change in hazard rate in a typical actuarial life table survival curve leading to change in conditional survival. The instantaneous hazard rate can be represented by the slope of the survival curve. At point A (Year 1), the slope is greater than at point B (Year 6), indicating a higher hazard rate at Year 1 compared with Year 6. This change in slope leads to a relative increase in conditional survival. The 5-year conditional survival after 1 year is the survival at point B divided by the survival at point A: S6/S1 = 0.115/0.399 = Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Ten-year overall survival for all patients with non-small cell lung cancer, grouped by ethnicity. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Five-year conditional survival for all patients with non-small cell lung cancer, grouped by ethnicity. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Five-year conditional survival for patients with non-small cell lung cancer, by stage and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 4 Five-year conditional survival for patients with non-small cell lung cancer, by stage and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 5 Five-year conditional survival for patients with non-small cell lung cancer, by sex and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

8 FIGURE 6 Five-year conditional survival for patients with non-small cell lung cancer, by age and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

9 FIGURE 7 Five-year conditional survival for patients with non-small cell lung cancer, by histology and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

10 FIGURE 7 Five-year conditional survival for patients with non-small cell lung cancer, by histology and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD "

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients  Camilla Maria T. Sagerup, MD, Milada.

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients  Camilla Maria T. Sagerup, MD, Milada.
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

Similar presentations

Ads by Google